Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to...
Saved in:
Main Authors: | Serena Cappuccio (Author), Maria Grazia Distefano (Author), Viola Ghizzoni (Author), Anna Fagotti (Author), Giovanni Scambia (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
by: Alberto A. Mendivil, et al.
Published: (2018) -
Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
by: Michelle Greenman, et al.
Published: (2024) -
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
by: Carlotta Defferrari, et al.
Published: (2012) -
Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
by: Wonkyo Shin, et al.
Published: (2018) -
The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience
by: Ching-Fen Hu, et al.
Published: (2015)